Comparative Proteomics Applied to the Avian Model of Ovarian Cancer

描述（由申请人提供）：目前，没有可靠的诊断生物标志物用于人类卵巢癌的早期检测。现在存在先进的蛋白质组学技术，以全面研究和发现复杂生物样品如血浆和组织中的诊断生物标志物。然而，在人类卵巢癌中识别候选生物标志物的主要障碍是缺乏合适的患者样本进行研究。由于母鸡在2岁时自发形成肿瘤，母鸡已成为卵巢癌的少数动物模型之一。这种可预测性沿着动物标本的广泛可用性使得母鸡成为研究卵巢癌发病和进展的可行模型。在此，我们建议使用先进的质谱和蛋白质组学技术研究国内母鸡蛋白质组作为时间的函数，以阐明预测卵巢癌的候选生物标志物。最终目标是将这些发现转化为生物学变异性更高的人类卵巢癌。在本提案执行过程中，主要研究员将接受生物科学多个领域的培训，以使其成为一名独立的科学家。 研究项目的公开说明。 卵巢癌是一种毁灭性的疾病，直到生存率很低的晚期才被发现。为了控制卵巢癌的死亡率，迫切需要早期诊断测试。该提案旨在确定可用于卵巢癌患者早期诊断的血源性蛋白质生物标志物。

DESCRIPTION (provided by applicant): Currently, there are no reliable diagnostic biomarkers for the early detection of ovarian cancer in humans. Advanced proteomics technology now exists to comprehensively investigate and discover diagnostic biomarkers in complex biological samples such as plasma and tissue. However, a major barrier to identifying candidate biomarkers in human ovarian cancer has been a lack of suitable patient samples from which to study. The domestic hen has emerged as one of the few animal models for ovarian cancer due to its spontaneous formation of tumors at two years of age. This predictability along with the widespread availability of animal specimens makes the hen a viable model for studying the onset and progression of ovarian cancer. Herein we propose to study the domestic hen proteome as a function of time using advanced mass spectrometry and proteomics technology to elucidate candidate biomarkers predicative of ovarian cancer. The ultimate goal is to translate these findings into human ovarian cancer where biological variability is much higher. During the course of this proposal, the principal investigator will be trained in multiple areas of biological sciences in an effort to transition him into an independent scientist. Public Description of Research Project. Ovarian cancer is a devastating disease that goes mostly undetected until the advanced stages where survival rates are poor. Early diagnostic tests are desperately needed to curb the mortality rates from ovarian cancer. This proposal seeks to identify blood-borne protein biomarkers that can be used for early diagnosis in ovarian cancer patients.